Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc has demonstrated robust revenue growth within its product lines, particularly with the Integrity patch, which is projected to contribute to more than 100% growth in revenue for 2025 compared to 2024. The company reported a 41% increase in its regenerative solutions business in the latest quarter and a 21% growth in international osteoarthritis pain revenue, indicating strong demand in both domestic and international markets. Furthermore, the significant 13% increase in overseas osteoarthritis pain revenue in Q1 highlights the company's successful expansion efforts and solidifies its position in the orthopedic medicines sector.

Bears say

Anika Therapeutics reported a 5.9% revenue decline to $27.8 million, alongside a recurring 8.2% decrease in revenues on a year-over-year basis, indicating persistent top-line challenges exacerbated by recent divestitures. The company also experienced production yield issues that negatively impacted gross margins, resulting in a gross margin of 56%, which fell short of the estimated 58%. Furthermore, the international revenue from osteoarthritis pain management experienced a significant 10% decrease, highlighting ongoing operational struggles that contribute to a negative outlook for the company's financial health.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.